Substance-P-lnduced Histamine Release from Human Nasal Mucosa in vitro

1995 ◽  
Vol 107 (1-3) ◽  
pp. 109-114 ◽  
Author(s):  
Katrin Schierhorn ◽  
Tilo Brunnée ◽  
Klaus-Detlev Schultz ◽  
Volker Jahnke ◽  
Gert Kunkel
Keyword(s):  
Substance P ◽  
Histamine Release ◽  
Nasal Mucosa ◽  
Human Nasal Mucosa

Pharmacological Characterization of Postjunctional α-Adrenoceptors in Human Nasal Mucosa

2005 ◽  
Vol 19 (5) ◽  
pp. 495-502 ◽  
Author(s):  
Michel R. Corboz ◽  
Maria A. Rivelli ◽  
Lori Varty ◽  
Jennifer Mutter ◽  
Mark Cartwright ◽  
...  
Keyword(s):  
Nasal Mucosa ◽  
Isometric Force ◽  
Ringer Solution ◽  
Predominant Role ◽  
Pharmacological Characterization ◽  
Human Nasal Mucosa ◽  
Force Transducers ◽  
Arteries And Veins

Background Functional α1- and α2-adrenoreceptor subtype pharmacology was characterized in an in vitro human nasal mucosa contractile bioassay. Methods Nasal mucosa was obtained from 49 donor patients and mucosal strips were placed in chambers filled with Krebs–Ringer solution and attached to isometric force transducers. Results Nonselective α-adrenoreceptor agonists epinephrine, norepinephrine, and oxymetazoline produced concentration-dependent contractions of isolated human nasal mucosa (pD2= 5.2, 4.9, and 6.5, respectively). The α2-adrenoreceptor agonist BHT-920 (10 μM)–induced contractions were blocked by yohimbine (0.01–1 μM) and prazosin (0.01–1 μM) inhibited the contractile response to the α1-adrenoreceptor agonist phenylephrine (10 μM). Histological analysis showed that phenylephrine and BHT-920 differentially contracted the arteries and veins of human nasal mucosa, respectively. Conclusion Our results indicate that functional α1- and α2-adrenoceptors are present and functional in human nasal mucosa. The a 2-adrenoceptors display a predominant role in contracting the veins and the α1-adrenoceptors appear to preferentially constrict the human nasal arteries.

Substance P enhances antigen-evoked mediator release from human nasal mucosa

Peptides ◽  
1996 ◽  
Vol 17 (1) ◽  
pp. 25-30 ◽  
Author(s):  
Claus R. Baumgarten ◽  
Angelika Witzel ◽  
Jörg Kleine-Tebbe ◽  
Gert Kunkel
Keyword(s):  
Substance P ◽  
Nasal Mucosa ◽  
Mediator Release ◽  
Human Nasal Mucosa

Substance P and Neurokinin A in Human Nasal Mucosa

1991 ◽  
Vol 4 (3) ◽  
pp. 228-236 ◽  
Author(s):  
James N. Baraniuk ◽  
Jens D. Lundgren ◽  
Michiko Okayama ◽  
Julie Goff ◽  
Joaquim Mullol ◽  
...  
Keyword(s):  
Substance P ◽  
Nasal Mucosa ◽  
Neurokinin A ◽  
Human Nasal Mucosa

Substance P induced histamine release from nasal mucosa of subjects with and without allergic rhinitis

2000 ◽  
Vol 49 (10) ◽  
pp. 520-523 ◽  
Author(s):  
G. Hanf ◽  
K. Schierhorn ◽  
T. Brunnée ◽  
O. Noga ◽  
D. Verges ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Substance P ◽  
Histamine Release ◽  
Nasal Mucosa

scholarly journals IgE-mediated histamine release from nasal mucosa is inhibited by SLPI (secretory leukocyte protease inhibitor) to the level of spontaneous release

1998 ◽  
Vol 7 (3) ◽  
pp. 217-220 ◽  
Author(s):  
U. Westin ◽  
E. Lundberg ◽  
K. Ohlsson
Keyword(s):  
Protease Inhibitor ◽  
Histamine Release ◽  
Nasal Mucosa ◽  
Secretory Leukocyte Protease Inhibitor ◽  
Cathepsin G ◽  
Low Molecular Weight ◽  
Spontaneous Release ◽  
Ige Mediated ◽  
Dose Dependent

The secretory leukocyte protease inhibitor (SLPI) is a low-molecular-weight inhibitor of proteases, such as elastase and cathepsin G which are released from leukocytes during phagocytosis. The purpose of this study was to determine whether or not SLPI is able to inhibit IgE-mediated histamine release. Nasal mucosa from 11 test subjects without atopic disposition was used for thisin vitrostudy. We found that SLPI inhibited histamine release in a dose-dependent way but was without influence on the spontaneous release.

Cytotoxic, genotoxic and pro-inflammatory effects of zinc oxide nanoparticles in human nasal mucosa cells in vitro

2011 ◽  
Vol 25 (3) ◽  
pp. 657-663 ◽  
Author(s):  
Stephan Hackenberg ◽  
Agmal Scherzed ◽  
Antje Technau ◽  
Michael Kessler ◽  
Katrin Froelich ◽  
...  
Keyword(s):  
Zinc Oxide ◽  
Nasal Mucosa ◽  
Zinc Oxide Nanoparticles ◽  
Oxide Nanoparticles ◽  
Human Nasal Mucosa

Anticholinergic Properties of Brompheniramine, Chlorpheniramine, and Atropine in Human Nasal Mucosa in Vitro

1998 ◽  
Vol 12 (2) ◽  
pp. 131-134 ◽  
Author(s):  
Sheen-Yie Fang ◽  
Howard M. Druce ◽  
James N. Baraniuk
Keyword(s):  
Nasal Mucosa ◽  
In Vitro Model ◽  
Anticholinergic Drugs ◽  
Anticholinergic Agents ◽  
Human Nasal Mucosa ◽  
Glandular Secretion ◽  
Explant Cultures ◽  
Vitro Model ◽  
Culture Supernatants

Brompheniramine and chlorpheniramine have anticholinergic activities, but the relative potency of these effects has not been well defined. The anticholinergic properties of brompheniramine, chlorpheniramine, and atropine were assessed in an in vitro model of human nasal mucosal glandular secretion. Methacholine was used as a cholinergic agonist to stimulate glandular secretion of 7F10-mucin. These drugs (0.01–1000 μM) or vehicle (saline) were added to explant cultures with and without 100 μM methacholine. 7F10-mucin concentrations were measured in culture supernatants after 2-hour incubations. The effective dose reducing methacholine-induced secretion (ED50) was determined. ED50 was 0.25 μM for atropine, 4.10 μM for brompheniramine, and 4.63 μM for chlorpheniramine. None of the anticholinergic drugs changed spontaneous glandular exocytosis. Brompheniramine and chlorpheniramine are equipotent anticholinergic agents in human nasal mucosa in vitro. Atropine was 16 to 19 times more potent.

Sign in / Sign up

Export Citation Format

Share Document